Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
. Mol Ecol Resour. 2014 May;14(3):606-15. doi: 10.1111/1755-0998.12205. Epub 2013 Dec 30. Mol Ecol Resour. 2014. PMID: 24266987
.
Otero MG, et al. Ann Clin Transl Neurol. 2018 Nov 9;6(1):154-160. doi: 10.1002/acn3.661. eCollection 2019 Jan. Ann Clin Transl Neurol. 2018. PMID: 30656193
.